Seaport Therapeutics (SPTX) news

Seaport Therapeutics Inc: Canaccord Genuity initiates coverage with buy rating; price target $28

Canaccord Genuity has initiated coverage on Seaport Therapeutics, Inc. (SPTX) with a "Buy" rating and a price target of $28 , according to a report dated October 14, 2026. This recommendation comes amid recent developments in the company’s clinical pipeline, including the Phase 1 clinical data for…

Mattel shares up 1.5% premarket after Seaport research partners upgrades to 'buy'

Mattel Inc. (MAT) shares rose 1.5% in pre-market trading on October 12, 2026, following an upgrade from Seaport Global Securities, which initiated coverage of the stock with a "Buy" recommendation . The move comes amid ongoing investor interest in the toy and entertainment company, which has been…

Jack Henry & Associates Inc: Piper Sandler raises to overweight from neutral

Piper Sandler has adjusted its price target for Jack Henry & Associates Inc. (JKHY) to $175 from $171, while maintaining a neutral rating . This follows a series of recent analyst actions, including upgrades from Raymond James and Seaport Global, which have set higher price targets and more bullish…

Fitch affirms Commonwealth of N Mariana Islands' Seaport revs at 'BB'; outlook stable

Fitch Ratings has affirmed the Commonwealth of the Northern Mariana Islands' Seaport revenue bonds at 'BB', with a stable outlook. The rating reflects the agency’s assessment of the seaport’s operational performance, financial stability, and its role in supporting regional economic activity. The…

Seaport Therapeutics - Plans global phase 2/3 glyphago trial in patients with gad in first half of 2027